Life Sciences Archive » March, 2016

Life Sciences - March, 2016

392 articles

• FTC Puts No-Authorized-Generic Pharma Deals In Crosshairs
• 3 Takeaways From FDA's Biosimilar Labeling Guidance
• Fired J&J Exec's Secret Romance Recalled By Witness
• Criminal Case Halts USPLabs Coverage Fight, Magistrate Says
• BMS Cancer Treatment Patent Survives Merck Attack, For Now
• Pa. Judge Limits Mom's Testimony In Paxil Birth Defect Trial
• Rising Star: Hogan Lovells' Adam Bellack
• Deals Rumor Mill: Medivation, Giordano's, SendGrid
• IRS Drops $119M Tax Bill To Carmex Fortune's Heirs
• GSK To Ease Access To Generic Drugs In Developing Countries
• Fed. Circ. Won't Rehear Case Over ITC's Digital Power
• Busy 1st Quarter For FCPA Enforcement
• Law And Regulation Of 3-D Printed Medical Devices
• FTC Sues Endo, Generics For Pay-For-Delay Agreements
• Shifting The Law Firm Business Development Paradigm
• Gilead Says Atty's Lie Kills Merck IP Behind $200M Jury Win
• Tyco Wants Directed Verdict In Insurer's $60M Heist Suit
• New FDA Rules Ease Access To Abortion Drug
• Pfizer, Allergan Say FTC Seeking More Info On Inversion Deal
• House Panel Subpoenas Fetal Tissue Research Cos.
• Valeant Seeks Breathing Room From Lenders
• Law360 Names Top Attorneys Under 40
• Houston IP Attorney Duo Leaves Baker Botts For Reed Smith
• FDA Approves Zika Test For Blood Donations
• SEC Fines, Bans Biotech Venture Capitalist Over $18M Fraud
• Sensus Healthcare Delays $20M IPO Amid Slumping Market
• How Biotechs Survive Despite Volatile Capital Markets
• How Employers Can Successfully Challenge Agency Guidance
• AbbVie Escapes Shire Investors' Suit Over Failed Merger
• Gilead Slams Merck's Bid To Boost $200M Award In IP Row
• USPTO Added Too Little Time To Supernus Patent, Suit Says
• Aveo Pays $4M To End SEC Claims It Misled Investors
• Arrowhead Ducks Investor Suit Over Hep B Drug Trial
• Feds Still Investigating Whether Biomet Broke Rules Abroad
• FDA Warning Wire: 'Virulent Pathogens' In Fancy Soaps
• Warner Says Mylan Misstatements Key To Doryx Antitrust Row
• Indivior Keeps Fighting For Resale Docs In Antitrust Case
• CIT Takes 3rd Option To Classify Imports Of Krill Oil
• Cancer-Focused Biotech Aeglea Sets Terms On $60M IPO
• Pharma Groups Back Pfizer In 3rd Circ. Pay-For-Delay Case
• TC Heartland's Restraints On ANDA Litigation Jurisdiction
• NJ Appeals Panel Affirms $11M J&J Pelvic Mesh Judgment
• Pure Green Coffee Firms Drained Of Weight Loss Claims
• New FDA Rules Put Onus On Doctors To Curb Opioid Abuse
• Affymetrix Says Thermo Fisher Deal Still Beats Ex-Execs'
• NY Launches E-Prescribing In Attempt To Curb Opioid Abuse
• Merck Seeks To Boost $200M Award In Gilead Drug IP Case
• Pediatric Cardiologist Testifies To Paxil-Heart Defect Link
• Allergan Faces NJ Patent Suit Over Generic ADHD Medication
• Supplement Distributor Didn't Lose On Deal, 2nd Circ. Told
• Benicar Maker Says NJ Law Limits Witness Coaching
• Actavis' Generic Lialda Still Too Early, Judge Finds
• Zimmer Replaces 2nd Bellwether Suit Over Knee Implants
• Generic Reglan Users Agree To Drop Amneal Claims In Philly
• Justices Reject P&G's Class Cert. Appeal In 'Snake Oil' Claim
• High Court Won't Hear Daiichi Sankyo's Patent Term Appeal
• Success Of Opioid Addiction Bill Would Rely On Funding
• Why Sanofi Is Required Reading For Securities Attorneys
• Mindless Lawyering: Is Doc Review 'The Practice Of Law'?
• SEC Hits Florida Accounting Firm Over MusclePharm Audit
• Abbott Whistleblower Defends $219M FCA Claim To Jury
• 7th Circ. Wants More Info In Suit Over Ill. Medicaid Drug Cap
• Generic Cos. Face Another Antitrust Suit Over Drug Prices
• Supple False Ad Suit Kept In Fed. Court, Then Nixed
• It's Time To Nix Homeopathic False Ad Claims, Hyland's Says
• Health Hires: New Partners At Proskauer, Perkins Coie
• Express Scripts Says Pharmacies Don't Show Conspiracy
• Stryker Toe Implant Suit Belongs In Fed Court, 5th Circ. Says
• 3 Charged In $1.2M Corporate Embezzlement Scheme
• Health-Focused 1315 Capital Nabs $179.5M Toward Fund
• J&J Unit Seeks Infringement Finding In Testing Strip Row
• Sandoz Shreds AbbVie's 'Misleading' Biosimilar Petition
• Gilead Hit With $200M Verdict In Merck Drug Patent Row
• Merck, Others Beat Eye Drop Dosage Suit For 2nd Time
• Paxil Linked To Heart Defects In Babies, Philly Jury Told
• FDA Floats Rules For Abuse-Deterrent Generic Opioids
• FCA Sampling Gets New Ammo In High Court's Tyson Ruling
• Genzyme Hits Sun With Suit Over Generic Leukemia Drug
• Senate Dems Push Regulators On Pot Biz Banking
• Indivior Says FDA Petition Didn't Delay Generic Suboxone
• Fed. Circ. Upholds Validity Of Depomed Drug Patents
• Commerce Opens New Chinese Refrigerant Compound Probe
• The Future Keeps Happening To Legal Services
• India Won't Cease Controversial Drug-Licensing Policy
• Endeavour Vision Nets $281M For Med-Tech Fund
• Yale To Fight Conn. Proposal To Revoke Tax-Exempt Status
• Frazier Healthcare Nabs $525M For Growth Buyout Fund
• Law360 Reveals 400 Largest US Firms
• Reasonable Royalty Takeaways From Fed. Circ. In 2015
• Shire, Actavis Feud Over Unresolved Issues At Lialda IP Trial
• Pa. Judge Reduces Claims In Essure Injury Suit
• 1st Circ. Affirms Wyeth's Win In Weight-Loss Drug Trial
• Icahn Beats Suits Over Short-Term Trades In Herbalife, Others
• Trial Judge Can't Award Atty Fees During Appeal, Firm Says
• Morgan Lewis Sheds Over 100 Attorneys After Bingham Deal
• 5 Firms On The Rise In 2016
• The Firms That Lost The Most Ground This Year
• Greenberg Traurig On Track To Become Biggest US Firm
• J&J Exec Says Married Doc's Relationship Violated Policy
• Pfizer Says Zoloft Defect Claims Still Suffer Lack Of Science
• Gilead Says Patent, Antitrust Claims Over HIV Drug Fail
• Merck Patent Claims Marred By 'Unclean Hands,' Gilead Says
• State Claims Too Late For GSK, Teva Lamictal Antitrust Row
• PTAB Approves Kyle Bass' 2nd Bid To Review MS Drug Patent
• KaloBios Investors Fight Hogan Lovells' Ch. 11 Fee Request
• Transfer Of Pelvic Mesh MDL Cases Is Premature, Judge Says
• Philly Judge Won't Consolidate Testosterone Cases
• Nicoll Davis Beats DQ Bid In Supplement Co.'s Kickback Row
• Novartis Pays $25M To SEC In Chinese FCPA Case
• Demystifying The Attorney-Client Privilege
• Norton Rose Fulbright Picks Up IP Pro From DLA Piper
• 4th Circ. Reverses Trademark Ruling On Bayer's 'Flanax'
• Philips Unit Pays $35M To Settle Sleep Mask Kickback Claims
• Ex-Warner Chilcott Exec Denied 'Early Preview' Of Trial
• Sidley Austin Hires 3 IP Litigators From Ropes & Gray
• Bristol-Myers To Pay Up To $600M For Autoimmune Biotech
• Correlation Or Cause: Brand-Name Drug Prescription Rates
• The Expansive Impact Of Acorda On Hatch-Waxman Cases
• Relator Nets Another $66M Payday In Novartis Kickback Suit
• Flying Solo: SEC's Growing Independence In FCPA Actions
• 1 Year Later: Omnicare's Effect On Opinion Liability
• Advaxis Must Face Claims Over 'Spring-Loaded' Stock Options
• US, Mexico Interpret NAFTA In Lilly's Canadian Patent Fight
• Merck Drug Patents Asserted Against Gilead Valid, Jury Finds
• Abbott Faces $219M FCA Trial Over Off-Label Stent Marketing
• Mylan Ruling Cements Del., NJ As Top ANDA Venues
• FDA Warning Wire: OTC Drug Dangers, Lead Contamination
• KaloBios Irons Out Issues With $14M Ch. 11 Financing Plan
• Amgen Hedges On Sandoz's High Court Biosimilar Petition
• Ex-Warner Chilcott Exec Asks To Limit Scope At Kickback Trial
• Ex-DLA Piper Product Liability Leader Joins Sidley in NY
• Detecting Marijuana-Impaired Drivers: A Lesson In History
• Actos Buyers Drop Generic Cos. From Pay-For-Delay Appeal
• NJ Pharmacy Pays $1.9M For Alleged Medicaid Overbilling
• Pfizer Urges 3rd Circ. Not To Revive Lipitor Antitrust Row
• Shkreli Judge Stays SEC Case, Offers Quick Criminal Trial
• Trial Pros: Choate Hall's Eric Marandett
• CIT Denies Amicus Bid In Supplement Customs Battle
• FDA Adds Black-Box Warning To Opioids
• FDA Challenges Direct-To-Consumer Genetic Tests
• Patients Target Bayer Over Essure Safety Amid FDA Scrutiny
• Insurer Blames Tyco Security For $60M Eli Lilly Drug Heist
• Sequenom Takes Fetal DNA Patent Row To High Court
• Anthem Hits Express Scripts With $15B Suit Over Pricing
• KaloBios Closer To $14M Ch. 11 Funding Despite Shkreli Ties
• MoFo Lures Ex-Baker Botts ITC Chair In DC
• Endo's Consumer Fraud Claim Tossed In Actavis False Ad Suit
• Frommer Lawrence Nabs Ex-DLA Piper Life Sciences Atty
• Daiichi Urges High Court To Allow Patent Term Extension
• Widow Wants 2nd Chance At Seeger Weiss Over Vioxx Deal
• ARCH Venture Partners Seeks $400M For 9th Fund
• 3rd Circ. Affirms J&J Win In Ex-Worker's Severance Suit
• FDA Eyes Ban On Powdered Medical Gloves
• Valeant Replacing CEO After Stock Drops, Investigations
• Affymetrix Snubs $1.5B Takeover Bid, Prefers Thermo Fisher
• FedEx Gets Drug Trafficking Claims Trimmed After DOJ Flub
• Justices Won't Decide Venue For Patent Interference Appeals
• ConforMIS Moves To Toss Suit Over $140M IPO
• Social Media As A Measure Of Cognitive Ability
• Is Student Loan Stress The New Norm For Law School?
• Olympus: Another Life Sciences Company Gets Hit Hard
• J&J Settling Morcellator Cases, Plaintiffs' Attorney Says
• 7 Best Practices For Managing An Associate's Personal Crisis
• Globus Dodges Subpoena In Doc's Patent Row With Medtronic
• Valeant Not On Verge Of Bankruptcy, CEO Tells Staff
• Insurer Wants Coverage Row Halted Until FCA Suit Ends
• Effexor Settlement No Shield For Antitrust Suit, FTC Says
• Fed. Circ. Affirms Warner Chilcott Atelvia Patents Are Invalid
• Froman Dismisses Notion Of Renegotiating TPP
• The Amarin Win: How Cahill Gordon Took On The FDA
• Senate OKs Prescription Drug Oversight Bill
• Patent Term Extension Considerations For Regulated Products
• Fed. Circ. Sets Wide Jurisdiction Rule In ANDA Patent Cases
• J&J Patients Won $502M Verdict With Rare Scope Of Evidence
• Braintree To Take Battle Over Laxative Patent To Fed. Circ.
• Aventis Escapes Claims That Clomid Warnings Fell Short
• Health Orgs Say Proposed Medicare Reform Will Harm Patients
• Arch Lambastes Eli Lilly's Sanctions Bid As 'Desperation'
• NY Doc Convicted For Role In Massive Oxycodone Pill Ring
• Gore-Tex Maker Says Antics In Stent IP Row Need Sanctions
• 2nd Circ. Tosses Pharma Rep.'s Malicious Prosecution Suit
• Cancer Treater's IPO Nets $102M; Device Maker Reduces Plans
• Endo, AbbVie Back Philly Testosterone Case Consolidation
• Pa. Judge Won't Undo 4th Philly Risperdal Verdict
• Patent Invalidation Need Not Nix Royalties, EU Adviser Says
• CORRECTED: Colorado Atty Accused Of Botching Med Tech Co.'s Patents
• How California Streamlined Costly, Time-Consuming Litigation
• Q&A With Covington & Burling's Marney Cheek
• Mylan Slams Warner's 'Overheated Rhetoric' In Doryx Row
• J&J Hit With $502M Verdict In 2nd Pinnacle Bellwether Trial
• A Historic Low For Drug Promotion Warning Letters
• Rethinking Seagate At The Supreme Court
• Biosimilar Makers Turn To IPRs Despite Mixed Results
• Wealth Management For Senior Partners
• OPINION: Missed Opportunity In Supreme Court Nomination
• Ex-QB Can't Pick Off Supplement False Ad Suit, 9th Circ. Told
• In His Own Words: 4 Key Garland Opinions
• Garland's High Court Nomination Battle Likely To Drag On
• Firm Says It Deserves All Fees From Pfizer's $785M Settlement
• Drug Co., Alaskan AG Drop Actions Against Each Other
• CDC's Opioid Stance Hurts Drug Cos. In Marketing Suits
• Judge Garland Could Bring New Consensus To High Court
• Hernia Mesh Maker Seeks Defense In Trade Secrets Fight
• Attorneys Weigh In On Obama's Supreme Court Pick
• Latham Advises Pet Meds Maker Putney In $200M Dechra Sale
• Amgen Patents For Cholesterol Drug Valid, Jury Finds
• Abbott's Handwritten Accord Is Binding, 7th Circ. Affirms
• FDA Stand On Drug-Combo Exclusivity Was Valid, Judge Says
• Texas Lawyer Accused Of Botching IUD Defect Case
• Shkreli Says Retrophin Must Pick Up $5M Legal Tab
• Fish Oil Class Couldn't Prove Loss, NJ Panel Says
• Vectura Inks $622M Deal For Fellow UK Inhaler Maker
• J&J Baby Sleep Aid False Ad Row Back In NJ State Court
• Q&A With WilmerHale's Rachael Kent
• Calif. Asks Innovator Drug Brands To Do The Impossible
• Real Estate Rumors: Ping An Insurance, Ares, EB-5 Deal
• Obama Picks Garland To Fill High Court Seat
• Hospira Urges Fed. Circ. To Keep On-Sale Bar For Patents
• Former J&J Exec Tells Jury Whistleblowing Got Him Fired
• GSK Can't Get Docs On Expert For Reed Smith Atty's Widow
• Hip MDL Plaintiffs' Attys Fight To Expedite Dying Patient's Suit
• Tenn. Hospitals Seek To Erase Some Claims In Meningitis MDL
• Chancery Asked To Dismiss $1.2B Volcano Merger Challenge
• McDermott Adds Arnold & Porter Partner As FDA Group Leader
• Sanofi Underplayed Dangers Of Chemo Drug, Suit Says
• 7th Circ. Kills Wrongful Firing Suit Against Zoetis
• FDA Warning Wire: Stimulants, Data Fraud, Device Lapses
• Deals Rumor Mill: Bashneft, Zoomlion, Ferro Corp.
• White & Case Snags Commercial Litigation Partner From MoFo
• Alere Hit With DOJ Subpoena In FCPA Investigation
• Valeant Stock Rocked Anew By Earnings, Default Warnings
• CDC Proposes Limits For Opioid Painkillers
• Ex-HR Consultant Avoids Prison For Inside Stock Tips
• Updating The Biotechnology Mission For The Bioeconomy
• Jury Awards $2.5M To Polo Horse Owners In Supplement Row
• Wright Medical Wants Bellwether Redo After $11M Verdict
• FDA Panel To Mull Abbott's Breakthrough Dissolving Stent
• PTAB Grants Kyle Bass' Bid To Review Acorda Drug Patents
• FTC Tells 3rd Circ. Wellbutrin Dismissal Misreads Actavis
• The 8 Firms GCs Can't Stop Talking About
• GCs Say These Firms Are Worth Paying Top Dollar For
• Gilead Halts 6 Zydelig Trials After Deaths
• Travelers Must Defend Actavis In Painkiller Suits, Court Told
• Zimmer Picks 2nd Bellwether Suit Over Knee Implants
• Contract Misquoted In 'Pill Mill' Row, 7th Circ. Hears
• GCs Name Most Elite Law Firms
• Deals Rumor Mill: Blackstone, Stemcentrx, Banco Santander
• CVC Capital Acquires Italian Generics Giant Doc Generici
• Q&A With Crowell & Moring's George Ruttinger
• Pfizer Says IRS Owes $8.3M In Interest On Late Refund
• Why Life Sciences Leases Are Not Your Average Transaction
• Group With Hedge Fund Ties Denied Review Of Enbrel Patent
• Pfizer Fights Zoloft MDL Plaintiffs' New Expert Reports
• 3rd Circ. Tosses Case Accusing Hangley Of Repping Fake Co.
• Hedge Fund Offers $10M KaloBios Stake, If Shkreli Benched
• Fresenius Seeks To Ax AIA Review Personally Filed By Bass
• J&J Ducks Motrin Injury Suit Over Man's Suicide
• Drug Co. May Hide Assets Instead Of Hire Attys, Investor Says
• Epstein Becker Nabs King & Spalding Health Partner
• Taxation With Representation: Fenwick, Skadden, Alston
• Senators Call On CMS To Investigate $3B Excess Drug Costs
• Kaye Scholer Partner Resigns In Wake Of Shkreli Indictment
• Medtronic Fights Investors' Appeal In Tainted Study Suit
• 3 Firms To Guide Uptick In Life Sciences IPOs Totaling $200M
• Omnicare Says High Court Ruling Vanquishes Investor Suit
• Travelers, Actavis Square Off Over Painkiller Suit Coverage
• Hedge Funds Can't Access Shares To Satisfy $21M Award
• Biotech Sets $75M IPO Terms While Another Yanks Deal
• Trial Pros: Knobbe Martens' Joseph Re
• Stem Cell Co.'s Trade Secrets Suit Dismissed As Repetitive
• Amarin Settlement Erodes Off-Label Promotion Enforcement
• 2nd Circ. Urged To Toss Pharma Rep.'s Suit Over Prosecution
• DOJ Attys Dish On Pharma, Device Fraud Landscape
• FDA Approves Teva's Generic Viagra Tablets
• Senate Passes Bill To Help Treat, Prevent Opioid Addiction
• PTAB Denies Hedge Fund's Bid For Painkiller Patent Reviews
• CVS Can't Be Held Liable For Doc's Bad Rx, NY Court Rules
• Poor Generic Drug Label Can Be Put On Novartis, Court Says
• IRS Can't Escape $100M Tax Fight Over Mylan Patent Deal
• Sunstein Kann Adds IP Pro From Wolf Greenfield In Boston
• Valeant Settles Suit Over $70M Worth Of 'Surprise' Invoices
• EU OKs Teva's $40B Allergan Buy Pending Cuts In UK, Ireland
• No Deal Too Small For US Antitrust Scrutiny
• Oversize Drug Packaging Suits Are A 'Waste' For Plaintiffs
• FTC Chief Tells Sens. Agency Not Ignoring Drug Price Hikes
• Novo Nordisk Hemophilia Drug Flouts Patent, ITC Judge Says
• Fed Circ. Urged To Invalidate Illumina Sequencing Patent
• SEC Recoups More Gilead Merger Insider Trading Profits
• Yeda Urges Fed. Circ. To Revive Protein Patent Row
• Deals Rumor Mill: Toshiba, Teva, Mediaset
• Most Anti-Bayer Expert Testimony Barred In Mirena IUD Suit
• Sanctions On Ex-Stryker Worker Over Evidence Upheld
• 2 Firms Steer $900M Becton Dickinson-Apax Respiratory JV
• Embattled Valeant Adds 3 Independent Directors To Board
• Recent Limitations On Patent Term Adjustment For 'A' Delay
• The Learned Intermediary Renaissance
• Wealth Management For Mid-Level Partners
• Berkeley Says Rival School Improperly Obtained Gene Patents
• New Medicare Drug Pay Model Invites Industry Clash
• Some Fraud Claims Resurrected In Testosterone MDL
• FDA Warning Wire: Pumps, Clinical Trials, Supplements
• NJ Doc Accused Of Taking Bribes In $100M Referral Scheme
• The Yates Memo: 6 Months Later
• Kyle Bass' Coalition Gets Review Of Cholesterol Drug Patents
• Amarin, FDA Finalize Free Speech Settlement
• J&J Unit Slams Diabetes Drug Blood Disorder Claims
• Diabetes-Focused Senseonics Sets $60M IPO
• Rex Medical Faces Philly Suit Over Vein Filter Injury
• Mylan, Ranbaxy Tell 3rd Circ. To Decertify Provigil Class
• Deals Rumor Mill: Toshiba, Nippon Telegraph, Orange SA
• Sanofi, Merck To End European Joint Vaccine Venture
• Claim Construction Post-Teva: 1st Year Of Fed. Circ. Review
• Fla. Senate Not High On Bill But OKs Medical Pot Revisions
• Omnicare Raises Bar On Exec Opinion Suits In 2nd Circ.
• Takeda, AstraZeneca Say Indian Co. Infringed Daliresp Patent
• Amgen Sues Sandoz Over Biosimilar Patent Talks
• BelHealth Says Geritrex Hid FDA Probe Before $14M Stake Deal
• Md. Hits J&J With Contact Lens Pricing Antitrust Suit
• Fed. Circ. Pushed To Ax Merck Antifungal Infringement Ruling
• PE-Backed Alvogen Bolsters Pipeline With Generics Co. Buy
• Pharma Co. Oversold Dialysis Drug Potential, Suit Claims
• Skin Graft Co. Raps Infringement Verdict At Fed. Circ.
• Deals Rumor Mill: DuPont, Sharp Corp., Americana Group
• 2nd Circ. Says Inyx CEO Still On The Hook For $1M
• Visium Asset Management Under Investigation By DOJ, SEC
• Best Practices For Motions Brief Writing: Part 2
• It's Too Early To Nix Hyland's False Ad Suit, Consumers Say
• 4 Drug Regulations Health Care Providers Must Know
• Judge Defines Scope Of On-Sale Bar Under AIA
• Zoloft MDL Plaintiffs Fight To Keep Expert Reports
• Nordion Settles SEC Case Over Ex-Worker's Russia Bribery
• J&J Fights To Keep Cherokee Risperdal Suit In Federal Court
• Jeffer Mangels Snags Former Alston & Bird IP Partner
• Drug Cos. Say False Claims Suit Hinges On High Court Case
• Franken Introduces Bill To End Tax Breaks For Drug Ads
• USPTO, Others Say Angiomax On-Sale Bar Shouldn't Apply
• Eli Lilly Seeks Sanctions In Contamination Coverage Fight
• Taxation With Representation: Davies, King & Spalding, K&L
• High Court Seeks Lamictal Buyers' Views On Antitrust Appeal
• Sanofi Suits Can't Survive Omnicare Ruling, 2nd Circ. Says
• Best Practices For Motions Brief Writing: Part 1
• Fresenius Requests Stay In Dialysis MDL To Ink Settlement
• Tips For Protecting Hatch-Waxman Stay After Lilly, Alcon
• New Rule 37(e) In Action: Lessons From First 3 Months
• NJ Doctor Escapes Most Claims In Suit Over Spinal Implants
• Insurer Can't Ax Bad-Faith Claim Over Heparin Defense Denial
• Cancer Drug Developer Syndax Prices $53M IPO Below Range
• AbbVie, Others Say Ill. Court Misapplied 7th Circ. Precedent
• 11th Circ. Lets $14M Boston Scientific Royalty Ruling Stand
• Tucker Ellis Snags Ex-Sidley Trial Duo For New Chicago Digs
• Generic Drug Cos. Face Union Action On Price-Fixing Claims
• Judge Skeptical Of Lifting Ex-MedImmune Exec's SEC Ban
• Deals Rumor Mill: Toshiba, Royal Philips, Samsonite
• Most Of Consumer's Expert's Testimony OK'd In J&J Trial
• NY AG Subpoenas Insurers On Hep C Drug Denials
• Trial Pros: White & Case's J. Mark Gidley
• NY AG Fines Endo For Falsely Advertising Opioid Opana ER
• Factors To Consider Before Making Any Patent Moves In Japan
• Trans Ova Fights $6M Verdict In Sex-Selection IP Case
• Major Firms Line Up At High Court To Fight AIA Claim Rules
• Zika Spurs New FDA Blood, Tissue Donation Guidelines
• GSK Asks High Court To Nix Avandia RICO Class Suit
• FTC Scores Patent-Related Docs In AndroGel Row
• GSK Says Generic 'Nasoflow' Infringes 'Flonase' Trademark
• Pfizer Must Face Blind Sales Rep's ADA Suit: 4th Circ.
• Mylan Accused Of 'Whopping Misstatements' In Doryx Row
• AstraZeneca Urges Del. Justices To End Nexium Fraud Case
• Pfizer Can't Escape Narrowed Off-Label Marketing FCA Suit
• Wealth Management For New Law Firm Partners
• McKesson Expands Into Canada With $2.2B Drugstore Buy
• Methods For Asserting Objections Under Amended Rule 34
• 11th Circ. Sinks Challenge To Instruction For Stiefel Fraud Jury
• Accel-KKR Latest To Target Cloud Cos. With IntegriChain Buy
• 2 Helpful Cases On Specific Causation Expert Testimony
• Diet Supplement Co. Owner Admits Using Cheaper Substitutes
• Wis. Justices Deal Policyholders Blow In Defective Part Suits
• One LLP Opens Shop With O'Melveny, Sheppard Mullin Pros
• CEO Rips 'Malicious' Feds After Beating Criminal Case
• Mintz Levin Snags Ex-Kilpatrick Townsend Patent Prosecutor
• Biotech IPOs Nudge 1 Firm Ahead of Peers In Quiet February
• Botched Supplement Killed 21 Polo Horses, Jury Told
• Big Pharma's Animated Ads To Get FDA Scrutiny
• Ex-NVE Exec Presses Bid To DQ Nicoll Davis In Kickback Row
• Pfizer Tells Zoloft MDL Judge Case Fails Without Experts
• FDA Warning Wire: Exoskeletons, Diet Drugs, Salmonella
• Fed. Circ. Asked To Nix PTAB's Power To Start AIA Reviews
• Deals Rumor Mill: Ball Corp., EQT Holdings, SABMiller
• Inclusion Of Bad Ingredient Not Covered, Wis. Justices Say
• Dying Hip Implant Patient Should Stay In MDL, Wright Says
• Olympus To Pay $646M To Settle Kickback, FCPA Probes
• Durbin Asks Abbott To Rethink 'Harsh' IT Worker Layoff Plan
• Key Securities Litigation Issues For Life Science Cos.